ANIMATION

HuLuc 63

Share this article with:

PDL BioPharma asked XVIVO to show how a novel humanized antibody, HuLuc 63, appears to induce anti-tumor effects by binding to a protein expressed only on the surface of myeloma cells. This initiates antibody-dependent cytotoxic activity which targets myeloma cells while leaving healthy cells intact.

Client


PDL BioPharma

Through their creative prowess and technical mastery, XVIVO is defining and redefining the very frontier of scientific animation. As science and medicine explore increasingly remote realms, their work provides a vital link allowing researchers and the general public to grasp visually an astonishing landscape of new possibilities.

Brian Greene, Professor Mathematics & Physics, Columbia University